Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Friday, April 20, 2018
 
Recommended for you
How Big Biotech Can Win Back Investors
The Wall Street Journal • Charley Grant
Goldman Sachs Asks ‘Is Curing Patients A Sustainable Business Model?’
CBS News • Cbs Sacramento
New affordable hepatitis C combination treatment shows 97% cure rate
Medical Xpress
Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative
The Guardian • Julia Kollewe
Biotech Analysis Central Pharma News: Novartis's Gene Therapy Catch, AstraZeneca's NASH Move, Clovis's Expanded Rubraca Market
Seeking Alpha • Terry Chrisomalis
Picking season
Week in Review
Medicare sets hospital outpatient payments for lymphoma drugs: 5 things to know
Becker's Hospital Review • Kelly Gooch
Be Ahead Of The Curve With Gilead Sciences
Seeking Alpha • Matthew Zeets
Why Gilead Looks Strong In First Quarter, But These Biotechs Are Shakier
Investor's Business Daily - Viewpoint RSS • Allison Gatlin
Running behind Gilead, Peninsula drug startup plots China dash for NASH
The Business Journals • Ron Leuty
 
Recommended for You
Biotechnology, Finance
How Big Biotech Can Win Back Investors
The Wall Street JournalCharley Grant
Big biotech stocks are trading at their lowest valuations in years, but don’t underestimate their ability to turn things around quickly. The first-quarter earnings season, which starts next week, will highlight the struggles of the big players—weak growth and few new products....
Share
Gilead Sciences, Hedge Funds
Goldman Sachs Asks ‘Is Curing Patients A Sustainable Business Model?’
CBS NewsCbs Sacramento
Turning the search for medical remedies into a numbers game, analyst Salveen Richter called potential "one shot cures" a bad business decision that will hurt a company's bottom line.
Share
Gilead Sciences
New affordable hepatitis C combination treatment shows 97% cure rate
Medical Xpress
An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by...
Share
Gilead Sciences, Health & Medicine
Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative
The GuardianJulia Kollewe
An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical trial results that offer hope to the 71 million people living with the disease worldwide. The...
Share
Biotechnology, Cancer
Biotech Analysis Central Pharma News: Novartis's Gene Therapy Catch, AstraZeneca's NASH Move, Clovis's Expanded Rubraca Market
Seeking AlphaTerry Chrisomalis
Summary Novartis acquires AveXis for $8.7 billion. AstraZeneca fronts $30 million upfront for NASH licensing deal with Ionis Pharmaceuticals. Clovis Oncology obtains FDA approval for expanded use of Rubraca. Welcome to Biotech Analysis Central Daily News, a daily news report and analysis...
Share
Biotechnology, Gilead Sciences
Picking season
Week in Review
Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs. In fact, the 12 investors who spoke to BioCentury are reveling under conditions they say...
Share
Gilead Sciences, Health Care Industry
Medicare sets hospital outpatient payments for lymphoma drugs: 5 things to know
Becker's Hospital ReviewKelly Gooch
Medicare has established the outpatient reimbursement rates for Gilead Science's and Norvartis' respective lymphoma treatments, according to a Reuters report. Here are five things to know. 1. The FDA initially approved Yescarta from Gilead Science in October and Novartis' Kymriah in August....
Share
Gilead Sciences, Health Finance
Be Ahead Of The Curve With Gilead Sciences
Seeking AlphaMatthew Zeets
Summary Gilead has had a rough couple of years with the precipitous fall of their HCV franchise. Future looks bright with HIV, Kite acquisition, and pipeline. Even if HCV revenues fell to 0 overnight, Gilead would still trade at 16.5 P/E with...
Share
Gilead Sciences
Why Gilead Looks Strong In First Quarter, But These Biotechs Are Shakier
Investor's Business Daily - Viewpoint RSSAllison Gatlin
Gilead Sciences' (GILD) viral franchises look strong heading into first-quarter earnings season, but fellow large caps Biogen (BIIB) and Celgene (CELG) are on shakier ground, an analyst said Wednesday. RBC analyst Brian Abrahams calls for Gilead to top expectations, with Biogen likely...
Share
Gilead Sciences
Running behind Gilead, Peninsula drug startup plots China dash for NASH
The Business JournalsRon Leuty
A Peninsula startup led by a former Gilead Sciences Inc. researcher is going another direction to jump ahead of the pack in one of the hottest commercial areas of biotech. Terns Pharmaceuticals Inc. of San Mateo said Wednesday that it has in-licensed...
Share